The in vitro CD8+ T cell activation, in vivo tumor suppression, tumor immune regulation, biodistribution, and adverse effects of PD1/CTLA‐4 BsAb were assessed and compared to free mixed monoclonal antibodies (aPD1 + aCTLA‐4). The gene discussed is CD8A; the disease is neoplasm.